ESTERS OR SALTS OF 2-HYDROXY-4-PROPYLCYCLOHEPTA-2,4,6-TRIENONE AND APPLICATION THEREOF IN PREPARATION OF ANIMAL ANTIBACTERIAL AGENTS AND GROWTH PROMOTERS USED IN FEED

Information

  • Patent Application
  • 20160332954
  • Publication Number
    20160332954
  • Date Filed
    February 17, 2014
    10 years ago
  • Date Published
    November 17, 2016
    8 years ago
Abstract
Esters or salts of 2-hydroxy-4-propyleyclohepta-2,4,6-trienone, and applications thereof in preparation of animal antibacterial agents and growth promoters used in feed. The esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone has a structural formula as shown in formula 1 or 2: in formula 1, R1 represents heptadecyl; and in formula 2, L is sodium, potassium, calcium, magnesium, zinc, copper or manganese. The esters or salts of 2-hydroxy-4-propyleyclohepta-2,4,6-trienone, as shown in formula 1 or 2, have high stability and safety, and good antibacterial and growth promotion effects, which make them preferable to be used as animal antibacterial agents and growth promoters in feed, and have a very good application prospect in the cultivation industry.
Description
FIELD OF THE INVENTION

The present invention relates to the field of animal antibacterial agents and growth promoters used in feed, specifically to the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone and applications thereof in preparation of animal antibacterial agents and growth promoters used in feed.


BACKGROUND OF THE INVENTION

As an active analogue of β-hinokitiol (also known as hinodiol, thujaplicin or 2-hydroxy-4-isopropyl-1-cyclohepta-2,4,6-trienone, which is a component of natural edible essential oil, and has been used as a food additive for years in Japan), 2-hydroxy-4-propylcyclohepta-2,4,6-trienone is researched and developed by Guangzhou Insighter Biotechnology Co., Ltd.


However, 2-hydroxy-4-propylcyclonepta-2,4,6-trienone (IST-009-001) has thermal instability and optical instability. To use 2-hydroxy-4-propylcyclohepta-2,4,6-trienone as a food additive, such problems must be solved.


SUMMARY OF THE INVENTION

The first object of the present invention is to provide esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone which are more stable, can promote the growth of livestock and are preferable to be used as feed additives and medical products.


The esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone of the present invention have a structural formula as shown in formula 1 or 2:




embedded image


Formula 1: wherein, R1 represents heptadecyl:




embedded image


Formula 2: wherein, L is sodium, potassium, calcium, magnesium, zinc, copper or manganese.


Preferably, L is magnesium, zinc, copper or manganese.


The second object of the present invention is to provide application of the above-mentioned esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone in preparation of animal antibacterial agents and growth promoters used in feed.


The animals include pigs, chickens, ducks, geese, beef cattle, dairy cattle, sheep, fish, shrimps, foxes, martens or raccoon dogs in all growth stages.


Dosage of the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone in animal feed is 0.1˜200 ppm.


The animal feed can be complete formula feed.


The esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone of the present invention, as shown in formula 1 or 2, have high stability and safety, and good antibacterial and growth promotion effects to be preferable using as animal antibacterial agents and growth promoters in feed, and have a very good application prospect in the cultivation industry.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an HPLC chromatogram of the manganese(II) 7-oxo-3-propylcyclohepta-1,3,5-trienolate in Embodiment 8.





DETAILED DESCRIPTION OF THE EMBODIMENTS

The present invention is described in further detail with reference to embodiments which shall not be regarded as limits in the present invention.


Embodiment 1
Structural Formula



embedded image


Preparation of 7-oxo-3-propylcyclohepta-1,3,5-trien-1-yl stearate (IST-009-050)
Preparation Process

2-hydroxy-4-propylcyclohepta-2,4,6-trienone (3.28 g, 20 mmol, 1 eq) and triethylamine (1˜10 eq) were dissolved in 100 ml of dichloromethane; at −10° C.˜25° C., to the resulting solution was added dropwise slowly with a mixture of n-octadecanoyl chloride (0.8˜5 eq) and about 30 ml of dichloromethane. The resulting reaction mixture was stirred for 3-8 h. Thin layer chromatography (TLC, developing solvent: petroleum ether:ethyl acetate=5:1), in which a new spot appeared while an impurity spot appeared at the initial spot, showed that almost all the reactants were consumed. Then the resulting reaction solution was washed with 100 ml of water and then with saturated salt water, but fluorescence was still observed at the initial spot of TLC. The organic phase was then wash with dilute aqueous solution of potassium hydroxide, mixed with 8 g of silica gel, and separated over a silica column, wherein the eluent was a mixture of petroleum ether, ethyl acetate and triethylamine in a ratio of 5:1:0.02. A pure product (7-oxo-3-propylcyclohepta-1,3,5-trien-1-yl stearate) was obtained, with a purity of 98%.


7-oxo-3-propylcyclohepta-1,3,5-trien-1-yl stearate: δH (CDCl3, 500 MHz) 7.068˜7.102 (2H, m), 6.982˜7.024 (1H, m), 6.879˜6.899 (1H, d), 2.593˜2.623 (2H, m), 2.493˜2.523 (2H, m), 1.731˜1.791 (2H, m), 1.606˜1.681 (2H, m), 1.389˜1.433 (2H, m), 1.256 (26H, m), 0.950˜0.979 (3H, m), 0.869˜0.890 (3H, m).


Embodiment 2
Structural Formula



embedded image


Preparation of potassium 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Potassium hydroxide (1˜3 eq) and 2-hydroxy-4-propylcyclohepta-2,4,6-trienone were dissolved in sequence in 150 ml of ethanol at room temperature, and the resulting solution was refluxed for 1-4 h and became clear, and was cooled to room temperature wherein no precipitate was observed. And then the solution was cooled to −40˜−20V to give a great amount of precipitate which was collected by filtration. The filter cake was washed with cold ethanol and then subjected to rotary evaporation to give a product (potassium 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 3
Structural Formula



embedded image


Preparation of sodium 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Sodium hydroxide (1˜5 eq) and 2-hydroxy-4-propylcyclohepta-2,4,6-trienone were dissolved in sequence in 100 ml of ethanol at room temperature. The resulting solution was reflux for 1˜5 h to (live precipitate, cooled to room temperature, stirred for 2 h, and then filtrated. The filter cake was washed with cold ethanol, and then subjected to rotary evaporation at 40° C. to give 15.9 g of product (sodium 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 4
Structural Formula



embedded image


Preparation of calcium 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Potassium hydroxide (1˜5 eq) was dissolved in 300 ml of water at room temperature. Then the mixture was cooled to room temperature, added with 2-hydroxy-4-propylcyclohepta-2,4,6-trienone (16.4 g, 100 mmol, 1 eq), and stirred at room temperature until complete dissolution. To the resulting solution was added 80 ml of aqueous solution of calcium chloride (0.4˜2 eq) dropwise to give a precipitate and the solution became viscous, then the solution was stirred for 2˜3 h at room temperature, and subjected to suction filtration. Filter cake was washed with 200 ml of water twice, subjected to vacuum drying, and then dried in an oven at 35° C. to give a product (calcium 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 5
Structural Formula



embedded image


Preparation of magnesium 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Potassium hydroxide (1˜5 eq) was dissolved in 300 ml of water at room temperature. Then the mixture was cooled to room temperature, added with 2-hydroxy-4-propylcyclohepta-2,4,6-trienone (16.4 g, 100 mmol, 1 eq), and stirred at room temperature until complete dissolution. To the resulting solution was added 80 ml of aqueous solution of hexahydrated magnesium chloride (0.4˜2 eq) dropwise to give a precipitate and the solution became viscous, then the solution was stirred for 2˜3 h at room temperature, and subjected to suction filtration. Filter cake was washed with 200 ml of water twice, subjected to vacuum drying, and then dried in an oven at 35 to give a product (magnesium 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 6
Structural Formula



embedded image


Preparation of zinc 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Potassium hydroxide (1˜5 eq) was dissolved in 300 ml of water at room temperature. Then the mixture was cooled to room temperature, added with 2-hydroxy-4-propylcyclohepta-2,4,6-trienone (16.4 g, 100 mmol, 1 eq), and stirred at room temperature until complete dissolution. To the resulting solution was added 100 ml of aqueous solution of zinc sulfate (0.4˜2 eq) dropwise to give a precipitate and the solution became viscous, then the solution was stirred for 2˜3 h at room temperature, and subjected to suction filtration. Filter cake was washed with 200 ml of water twice, subjected to vacuum drying, and then dried in an oven at 35° C. to give a product (zinc 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 7
Structural Formula



embedded image


Preparation of copper 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Potassium hydroxide (1˜5 eq) was dissolved in 300 ml of water at room temperature. Then the mixture was cooled to room temperature, added with 2-hydroxy-4-propylcyclohepta-2,4,6-trienone (16.4 g, 100 mmol, 1 eq), and stirred at room temperature until complete dissolution. To the resulting solution was added 100 ml of aqueous solution of copper chloride (0.4˜2 eq), dropwise to give a precipitate and the solution became viscous, then the solution was stirred for 2˜3 h at room temperature, and subjected to suction filtration. Filter cake was washed with 200 ml of water twice, subjected to vacuum drying, and then dried in an oven at 35° C. to give a product (copper 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 8
Structural Formula



embedded image


Preparation of manganese 7-oxo-3-propylcyclohepta-1,3,5-trienolate

Potassium hydroxide (1˜5 eq) was dissolved in 300 ml of water at room temperature. Then the mixture was cooled to room temperature, added with 2-hydroxy-4-propylcyclohepta-2,4,6-trienone (16.4 g, 100 mmol, 1 eq), and stirred at room temperature until complete dissolution. To the resulting solution was added 100 ml of aqueous solution of manganese sulfate (0.4˜2 eq) dropwise to give a precipitate and the solution became viscous, then the solution was stirred for 2˜3 h at room temperature, and subjected to suction filtration. Filter cake was washed with 200 ml of water twice, subjected to vacuum drying, and then dried in an oven at 35° C. to give a product (manganese 7-oxo-3-propylcyclohepta-1,3,5-trienolate), a purity of which was 99% by HPLC.


Embodiment 9
Thermal stability test of 7-oxo-3-propylcyclohepta-1,3,5-trien-1-yl stearate in high temperature

The prepared 7-oxo-3-propylcyclohepta-1,3,5-trien-1-yl stearate (IST-009-050) was mixed with corncob powder to obtain a premix with a mass fraction of 2%. Samples (the premix) were placed in crucibles and spread, and then placed in oven at 60° C. or eat for different durations. Then 1.0 g of each of the samples (three duplicate samples from each sample) and 50 ml of ethanol were added into a conical flask, subjected to sonication for 10 min, and then filtrated through filter paper. The filtrate was transferred into a 50 ml volumetric flask, topped up to the final volume with ethanol, and then filtered with a 0.45 μm microporous membrane and subjected to HPLC analysis.


Chromatographic Parameters


Column: Wondasil C18 (250 mm×4.6 mm, 5 μm);


Mobile Phase: acetonitrile (100%);


Detection Wavelength: 220 nm;


Column Temperature: 25° C.;


Injection Volume: 20 μL;


Flow Rate: 0.8 or 1.0 ml/min.


Results of the stability test were as shown in table 1.


Results showed that the thermal stability of 7-oxo-3-propylcyclohepta-1,3,5-trien-1-yl stearate is better than the unesterified 2-hydroxy-4-propylcyclohepta-2,4,6-trienone (IST-009-001), but not satisfactory yet.









TABLE 1







Results of thermal stability test of 7-oxo-


3-propylcyclohepta-1,3,5-trien-1-yl stearate










Compound
Temperature (° C.)
Time (h)
Content (%)













IST-009-050


2.0


IST-009-050
60
22
0.84


IST-009-050
80
22
0.61


IST-009-050
60
44
0.35


IST-009-050
80
44
0.03


IST-009-050
60
68
0.14


IST-009-050
80
68
0


IST-009-001
80
22
0


IST-009-001
80
44
0


IST-009-001
80
68
0









Embodiment 10
Thermal stability test of different metal salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone

Each of the metal salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone prepared in Embodiments 2-6 was mixed with corncob powder to obtain a premix with a mass fraction of 2%. Samples (the premix) were placed in crucibles and spread, and then placed in oven at 100° C. for different durations. Then 1.0 g of each of the samples (three duplicate samples from each sample) and 50 ml of ethanol were added into a conical flask, subjected to sonication for 10 min, and then filtrated through filter paper. The filtrate was transferred into a 50 ml volumetric flask, topped up to the final volume with ethanol, and then filtered with a 0.45 μm microporous membrane and subjected to HPLC analysis. Results of the thermal stability test were as shown in table 2.


Chromatographic Parameters


Column: Wondasil C18 (250 mm×4.6 mm, 5 μm);


Mobile phase: methanol/40 mM ammonium acetate (65:35, v/v; pH 4):


Detection Wavelength: 220 nm;


Column Temperature: 25° C.;


Injection Volume: 20 μL;


Flow Rate: 0.8 or 1.0 ml/min.


Results showed that the thermal stability of the metal salts of IST-009-001 were all significantly enhanced in comparison with IST-009-001, wherein the magnesium, copper and manganese salts have the highest thermal stability.









TABLE 2







Results of thermal stability test of different metal


salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone












Residual
Residual



Initial
content at
content at



content
100° C. for
100° C. for


Compound
(%)
20 h (%)
40 h (%)













Sodium 7-oxo-3-
2.0
1.31
1.11


propylcyclohepta-1,3,5-trienolate


Potassium 7-oxo-3-
2.0
1.43
1.13


propylcyclohepta-1,3,5-trienolate


Calcium 7-oxo-3-
2.0
1.73
1.67


propylcyclohepta-1,3,5-trienolate


Magnesium 7-oxo-3-
2.0
1.99
1.99


propylcyclohepta-1,3,5-trienolate


Zinc 7-oxo-3-
2.0
1.85
1.83


propylcyclohepta-1,3,5-trienolate


2-hydroxy-4-propylcyclohepta-
2.0
0
0


2,4,6-trienone


Copper 7-oxo-3-
2.0
1.99
1.98


propylcyclohepta-1,3,5-trienolate


Manganese 7-oxo-3-
2.0
1.99
1.98


propylcyclohepta-1,3,5-trienolate









Embodiment 11
Optical stability test of different metal salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone

Each of the metal salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone prepared in Embodiments 2-6 was mixed with corncob powder to obtain a premix with a mass fraction of 2%. Samples (the premixes) were spread in a stability test chamber and subjected to illumination at 4500-5000 lux for 5 days. Then 1.0 g of each of the samples (three duplicate samples from each sample) and 50 ml of ethanol were added into a conical flask, subjected to sonication for 10 min, and then filtrated through filter paper. The filtrate was transferred into a 50 ml volumetric flask, topped up to the final volume with ethanol, and then filtered with a 0.45 μm microporous membrane and subjected to HPLC analysis.


Column: WondasilC18 (250 mm×4.6 mm, 5 μm);


Mobile Phase: methanol/40 mM ammonium acetate (65:35, v/v; pH 4):


Detection Wavelength: 220 nm;


Column Temperature: 25° C.;


Injection Volume: 20 μL;


Flow Rate: 0.8 or 1.0 ml/min.


Results of the stability test were as shown in table 3. The results showed that the optical stability of the salts was enhanced, wherein results of the manganese, copper, zinc and magnesium salts were most significant.









TABLE 3







Optical stability of different metal salts of


2-hydroxy-4-propylcyclohepta-2,4,6-trienone











Residual



Initial
content of



content
5 days later


Compound
(%)
(%)












Sodium
2.0
0.05


7-oxo-3-propylcyclohepta-1,3,5-trienolate


Potassium
2.0
0.17


7-oxo-3-propylcyclohepta-1,3,5-trienolate


Calcium
2.0
0.89


7-oxo-3-propylcyclohepta-1,3,5-trienolate


Magnesium
2.0
1.52


7-oxo-3-propylcyclohepta-1,3,5-trienolate


Zinc
2.0
1.77


7-oxo-3-propylcyclohepta-1,3,5-trienolate


IST-009-001
2.0
0


(2-hydroxy-4-propylcyclohepta-2,4,6-trienone)


Copper
2.0
1.9


7-oxo-3-propylcyclohepta-1,3,5-trienolate


Manganese
2.0
1.96


7-oxo-3-propylcyclohepta-1,3,5-trienolate









Embodiment 12
Applications of magnesium 7-oxo-3-propylcyclohepta-1,3,5-trienolate in broiler feeds

500 1-day-aged, healthy, fast-grown yellow feather broilers (female) in the same growing state and similar in weight were randomly divided into five groups according to table 4, 100 broilers in each group. Broilers of each group were fed with different dosages of magnesium 7-oxo-3-propylcyclohepta-1,3,5-trienolate or 2-hydroxy-4-propylcyclohepta-2,4,6-trienone. The broilers were kept in cages and fed with food and water ad libitum during a 30 days test period, wherein weight gain and feed conversion efficiency of the broilers fed with magnesium 7-oxo-3-propylcyclohepta-1,3,5-trienolate had been significantly improved.









TABLE 4







Grouping of tested animals, and dosage of additives












Quantity






of the

Dosage
Administra-


Group
broilers
Additives
(ppm)
tion





1
100
Blank Control

Mixed with






feed


2
100
Magnesium
2.5
Mixed with




7-oxo-3-propylcyclohepta-

feed




1,3,5-trienolate


3
100
Magnesium
5.0
Mixed with




7-oxo-3-propylcyclohepta-

feed




1,3,5-trienolate


4
100
2-hydroxy-4-propylcyclo-
2.5
Mixed with




hepta-2,4,6-trienone

feed


5
100
2-hydroxy-4-propylcyclo-
5.0
Mixed with




hepta-2,4,6-trienone

feed
















TABLE 5







Application effects of magnesium 7-oxo-3-propylcyclohepta-


1,3,5-trienolate in broiler feeds














Average

Average




Initial
weight
Consump-
daily
Feed



weight
gain
tion
weight gain
conversion


Group
(g)
(g)
(kg)
(g)
efficiency















1
41.03
735
151.78
24.5
2.065


2
41.24
785
155.94
26.2
1.984


3
42.47
798
151.54
26.6
1.899


4
42.62
783
156.66
26.1
1.988


5
41.18
804
153.24
26.8
1.906








Claims
  • 1. Esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone, having a structural formula as shown in formula 1:
  • 2. The esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone according to claim 1, wherein L is magnesium, zinc, copper or manganese.
  • 3. A method of using the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone according to claim 1 as an animal antibacterial agent, comprising the step of administering the animal antibacterial agent to an animal.
  • 4. The method according to claim 3, wherein said animal includes pigs, chickens, ducks, geese, beef cattle, dairy cattle, sheep, fish, shrimp, foxes, martens or raccoon dogs in all growth stages.
  • 5. The method according to claim 3, wherein a dosage of the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone in animal feed is 0.1˜200 ppm.
  • 6. A method of using the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone according to claim 1 in preparation of growth promoters comprising the step of adding the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone to animal feed.
  • 7. The method according to claim 6, wherein said animal includes pigs, chickens, ducks, geese, beef cattle, dairy cattle, sheep, fish, shrimp, foxes, martens or raccoon dogs in all growth stages.
  • 8. The method according to claim 6, wherein a dosage of the esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone in animal feed is 0.1˜200 ppm.
Priority Claims (1)
Number Date Country Kind
201410013396.3 Jan 2014 CN national
PCT Information
Filing Document Filing Date Country Kind
PCT/CN2014/072126 2/17/2014 WO 00